. "lung cancer" . "1"^^ . "2013-10-31+01:00"^^ . "NS10285" . "2011-08-08+02:00"^^ . "1"^^ . " VEGFR" . . . . "6"^^ . "6"^^ . . . "http://www.isvav.cz/projectDetail.do?rowId=NS10285"^^ . . . "2009-01-01+01:00"^^ . "Pr\u016Fkaz minim\u00E1ln\u00ED syst\u00E9mov\u00E9 nemoci u karcinomu plic pomoc\u00ED dostate\u010Dn\u011B senzitivn\u00EDch a specifick\u00FDch marker\u016F cestou qRT-PCR jje technicky sch\u016Fdn\u00FD. Exprese biomarker\u016F minim\u00E1ln\u00ED systmov\u00E9 nemoci m\u016F\u017Ee slou\u017Eit k tailorov\u00E1n\u00ED syst\u00E9mov\u00E9 l\u00E9\u010Dby."@cs . . " c-met" . " polymerase chain reaction" . "lung cancer; polymerase chain reaction; messenger RNA; minimal residual disease; c-met; hTERT; EGFR; VEGFR; CEA."@en . . " EGFR" . . . "Clinical significance of minimal residual disease in patients with operable lung cancer"@en . " messenger RNA" . "2011-12-31+01:00"^^ . . . "Minimal systemic disease detection in lung cancer patients is technically feasible using sufficiently sensitiv and specific markers for qRT-PCR. Biomarkers expression of the minimal systemic disease can be used to guide further systemic treatment."@en . . " hTERT" . "Evaluation of clinical use of minimal residual disease (MRD) detection in prospective controlled systems (blood and bone marrow) in a group of 100-120 patients with non-smallcellular lung cancer (NSCLC). Prospective comparison of MRD circulating markers\u00B4 expression, bone marrow expression and reaction to local and systemic therapy in pacients with lung cancer. Monitoring of MRD in blood at 6month intervals and in bone marrow at one year intervals in correlation with clinical follow-up of patients and monitoring of the disease-free interval and overall survival. If dependency between MRD and patients\u00B4 prognosis is confirmed, MRD may be utilized in monitoring the effect of local and systemic therapy using specific markers (CEA, c-met messenger RNA, EGFR and VEGFR mRNA, mRNA telomerase, CC-20). Evaluation of possible utilisation of MRD in tailoring and monitoring response to local and systemic therapy in operable stage of NSCLC."@en . . . "V\u00FDznam stanoven\u00ED minim\u00E1ln\u00ED rezidu\u00E1ln\u00ED choroby u nemocn\u00FDch s operabiln\u00EDm plicn\u00EDm karcinomem" . "Vyhodnocen\u00ED mo\u017Enosti klinick\u00E9ho vyu\u017Eit\u00ED detekce minim\u00E1ln\u00ED rezidu\u00E1ln\u00ED nemoci (MRD) v prospektivn\u011B kontrolovateln\u00FDch syst\u00E9mech, tedy perifern\u00ED krvi a kostn\u00ED d\u0159eni, u 100-120 pacient\u016F s nov\u011B diagnostikovan\u00FDm nemalobun\u011B\u010Dn\u00FDm plicn\u00EDm karcinomem, prospektivn\u00ED porovn\u00E1n\u00ED exprese cirkuluj\u00EDc\u00EDch marker\u016F MRD a marker\u016F MRD v kostn\u00ED d\u0159eni s reakc\u00ED na lok\u00E1ln\u00ED a syst\u00E9movou terapii u nemocn\u00FDch c karcinomem plic a d\u00E1le monitorov\u00E1n\u00ED hladin marker\u016F MRD v perifern\u00ED krvi v p\u016Flro\u010Dn\u00EDch a v kostn\u00ED d\u0159eni v ro\u010Dn\u00EDch intervalech p\u0159i sou\u010Dasn\u00E9 klinick\u00E9 dispenzarizaci a sledov\u00E1n\u00ED \u010Dasu do progrese a celkov\u00E9ho p\u0159e\u017Eit\u00ED s perspektivou vyu\u017Eit\u00ED pro monitoraci efekt\u016F lok\u00E1ln\u00ED a syst\u00E9mov\u00E9 l\u00E9\u010Dby NSCLC pomoc\u00ED trendov\u00E1n\u00ED s\u00E9rov\u00FDch hladin vybran\u00FDch marker\u016F (karcinoembryon\u00E1ln\u00ED antigen -CEA, c-met messenger RNA, EGFR a VEGFR mRNA, mRNA telomer\u00E1zy, cytokeratin CK 20). Posouzen\u00ED mo\u017Enosti vyu\u017Eit\u00ED stanoven\u00ED MRD k tailorov\u00E1n\u00ED a monitorov\u00E1n\u00ED odpov\u011Bdi na lok\u00E1ln\u00ED a syst\u00E9movou terapii operabiln\u00EDch stadi\u00ED nemalobun\u011B\u010Dn\u00E9 rakoviny plic" . " minimal residual disease" . . "0"^^ .